Fate Therapeutics Inc. (FATE)
NASDAQ: FATE
· Real-Time Price · USD
1.05
0.04 (3.96%)
At close: May 16, 2025, 3:59 PM
1.08
2.37%
After-hours: May 16, 2025, 05:23 PM EDT
Fate Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2020 |
|---|---|---|---|
| Upfront Fee And Equity Premium Revenue | 31.2M | 23.1M | 6.5M |
| Upfront Fee And Equity Premium Revenue Growth | +35.06% | +255.38% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 13.77M | 15.26M | 20.8M | 17.25M | 20.86M | 17.93M | 18.95M | 22.62M | 21.94M | 21.58M | 21.55M | 20.35M | 20.74M | 16.93M | 15.72M | 12.17M | 12.5M | 10.31M | 8.35M | 7.5M | 7.73M | 6.67M | 6.35M | 5.27M | 5.35M | 4.31M | 4.08M | 3.82M | 3.6M | 3.38M | 2.79M | 2.67M | 3.03M | 2.45M | 2.61M | 2.25M | 2.6M | 2.56M | 2.35M | 2.69M | 2.76M |
| Selling, General, and Administrative Revenue Growth | -9.76% | -26.63% | +20.58% | -17.28% | +16.28% | -5.35% | -16.24% | +3.09% | +1.66% | +0.13% | +5.92% | -1.89% | +22.48% | +7.74% | +29.17% | -2.66% | +21.21% | +23.49% | +11.30% | -2.92% | +15.86% | +5.12% | +20.42% | -1.50% | +24.22% | +5.54% | +6.94% | +5.88% | +6.50% | +21.38% | +4.46% | -11.97% | +23.70% | -6.13% | +16.10% | -13.57% | +1.84% | +8.68% | -12.60% | -2.39% | n/a |
| Research and Development Revenue | 29.14M | 28.8M | 34.65M | 34.6M | 27.32M | 26.93M | 34.27M | 40.88M | 65.63M | 87.19M | 79.82M | 81.31M | 72.14M | 69.51M | 53.13M | 48.02M | 44.85M | 38.98M | 30.69M | 26.67M | 29.28M | 25.21M | 23.2M | 21.63M | 17.73M | 14.1M | 13.64M | 16.82M | 11.48M | 9.89M | 8.58M | 7.93M | 7.97M | 6.23M | 6.8M | 6.78M | 6.64M | 5.43M | 5M | 4.86M | 4.57M |
| Research and Development Revenue Growth | +1.18% | -16.89% | +0.13% | +26.68% | +1.43% | -21.43% | -16.15% | -37.72% | -24.73% | +9.24% | -1.83% | +12.71% | +3.78% | +30.84% | +10.63% | +7.07% | +15.06% | +27.00% | +15.09% | -8.91% | +16.14% | +8.65% | +7.26% | +22.02% | +25.78% | +3.36% | -18.90% | +46.53% | +16.07% | +15.26% | +8.21% | -0.49% | +27.87% | -8.44% | +0.32% | +2.20% | +22.14% | +8.59% | +3.01% | +6.33% | n/a |